Low dose iron treatments induce a DNA damage response in human endothelial cells within minutes

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Mollet, Inês G ^a   Patel, Dilipkumar ^a   Govani, Fatima S ^a,b   Giess, Adam ^a,b   Paschalaki, Koralia ^a   Periyasamy, Manikandan ^a   Lidington, Elaine C ^a   Mason, Justin C ^a   Jones, Michael D ^a   Game, Laurence ^a   Ali, Simak ^a   Shovlin, Claire L ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOM SYNDROME HELICASE; CELL DNA; CITRIC ACID; FANCONI ANEMIA GROUP G PROTEIN; FERROUS ION; PROTEIN P53; H2AFX PROTEIN, HUMAN; HISTONE; IRON; TP53 PROTEIN, HUMAN;

ARTICLE; BIOLOGICAL FUNCTIONS; BLM GENE; CELL CYCLE; CELL VACUOLE; CELLULAR STRESS RESPONSE; CLUSTER ANALYSIS; CONTROLLED STUDY; CULTURE MEDIUM; DNA DAMAGE; DNA REPAIR; ENDOTHELIUM CELL; EXON; FANCG GENE; GENE; GENE CLUSTER; GENE EXPRESSION; GENE NUMBER; GENE TARGETING; GENETIC DATABASE; H2AFX GENE; HUMAN; HUMAN CELL; IRON THERAPY; ONTOLOGY; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN STABILITY; RNA SEQUENCE; RNA TRANSCRIPTION; VALIDATION STUDY; COMET ASSAY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; MICROCIRCULATION; PHOSPHORYLATION; SEQUENCE ANALYSIS; UMBILICAL VEIN ENDOTHELIAL CELL;

CELL CYCLE; CITRATES; CLUSTER ANALYSIS; COMET ASSAY; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; EXONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTONES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IRON; MICROCIRCULATION; PHENOTYPE; PHOSPHORYLATION; SEQUENCE ANALYSIS, RNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84959422551     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147990     Document Type: Article

References (63)

1. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011; 117: 4425-33. doi: 10.1182/blood- 2011-01-258467 PMID: 21346250
2. Musallam KM, Cappellini MD, Taher AT. Iron overload in β-thalassemia intermedia: an emerging concern. Curr Opin Hematol. 2013; 20(3):187-92 doi: 10.1097/MOH.0b013e32835f5a5c PMID: 23426199
3. Gaenzer H, Marschang P, Sturm W, Neumayr G, Vogel W, Patsch J, et al. Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol. 2002; 40(12): 2189-94. PMID: 12505233
4. Akhlaghpoor S, Hoseini M, Jafarisepehr A. Association of iron overload based quantitative T2∗ MRI technique and carotid intima-media thickness in patients with beta-thalassemia: a cross-sectional study. BMC Cardiovasc Disord. 2010 Dec 31; 10: 62. doi: 10.1186/1471-2261-10-62 PMID: 21194437
5. Chan S, Chen MP, Cao JM, Chan GC, Cheung YF. Carvedilol Protects against Iron-Induced Microparticle Generation and Apoptosis of Endothelial Cells. Acta Haematol. 2014; 132:200-210. PMID: 24662949
6. Kartikasari AE, Georgiou NA, Visseren FL, van Kats-Renaud H, van Asbeck BS, Marx JJ. Endothelial activation and induction of monocyte adhesion by non transferrin-bound iron present in human sera. FASEB J. 2006; 20: 353-5 PMID: 16368718
7. World Health Organization. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva 2002. Available at http://www.who.int/whr/2002/en. Accessed 5 January 2016
8. Lin L, Valore EV, Nemeth E, Goodnough JB, Gabayan V, Ganz T. Iron-transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood 2007; 110: 2182-9 PMID: 17540841
9. Hutchinson C, Al-Ashgar W, Liu DY, Hider RC, Powell JJ, Geissler CA. Oral ferrous sulfate leads to a marked increase in pro-oxidant nontransferrin-bound iron. Eur J Clin Invest. 2004; 34: 782-4 PMID: 15530152
10. Dresow B, Petersen D, Fischer R, Nielsen P. Non-transferrin-bound iron in plasma following administration of oral iron drugs. Biometals 2008; 21(3): 273-6 PMID: 17851733
11. Schümann K, Solomons NW, Romero-Abal ME, Orozco M, Weiss G, Marx J. Oral administration of ferrous sulfate, but not of iron polymaltose or sodium iron ethylenediaminetetraacetic acid (NaFeEDTA), results in a substantial increase of non-transferrin-bound iron in healthy iron-adequate men. Food Nutr Bull. 2012; 33(2): 128-36. PMID: 22908694
12. Breuer W, Herschko C, Cabantchik ZI. The importance of non-transferrin-bound iron in disorders of iron metabolism. Transfus Sci. 2000; 23: 185-192 PMID: 11099894
13. Scheiber-Mojdehkar B, Lutzky B, Schaufler R, Sturm B, Goldenberg H. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric sacharate: no correlation to peroxide generation. J Am Soc Nephrol. 2004; 15: 1648-1655 PMID: 15153577
14. Van Campenhout A, Van Campenhout C, Lagrou A, Manuel-y-Keenoy B. Iron-induced oxidative stress in haemodialysis patients: a pilot study on the impact of diabetes. Biometals 2008; 21(2): 159-70. PMID: 17585373
15. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014; 46(7): 678-84. doi: 10.1038/ng.2996 PMID: 24880340
16. Nelson M, Poulter J. Impact of tea drinking on iron status in the UK: a review. J Hum Nutr Diet. 2004 Feb; 17(1):43-54. PMID: 14718031
17. Scientific Advisory Committee on Nutrition. SACN Iron and Health Report. Available at http://www.sacn.gov.uk/reports-position-statements/reports/sacn-iron-and-health-report.html Accessed 5 January 2016
18. Shovlin CL. Hereditary hemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev. 2010; 24(6): 203-19. doi: 10.1016/j.blre.2010.07.001 PMID: 20870325
19. Shovlin CL, Awan IA, Abdulla FN. Iron treatments may precipitate nosebleeds in hereditary hemorrhagic telangiectasia. Angiogenesis 2015; 18: 566-567; full manuscript in review (supplied).
20. Braverman IM, Keh A, Jacobson BS. Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J Invest Dermatol. 1990 95(4): 422-7 PMID: 2212727
21. Shovlin CL. Pulmonary arteriovenous malformations. Am J Respir Crit Care Med. 2014; 190(11): 1217-28. doi: 10.1164/rccm.201407-1254CI PMID: 25420112
22. Shovlin CL, Angus G, Manning RA, Okoli GN, Govani FS, Elderfield K, et al. Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension. PLoS One 2010; 5(2): e9154. doi: 10.1371/journal.pone.0009154 PMID: 20174619
23. Dentelli P, Rosso A, Orso F, Olgasi C, Taverna D, Brizzi MF. MicroRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression. Arterioscler Thromb Vasc Biol. 2010; 30(8): 1562-8 doi: 10.1161/ATVBAHA.110.206201 PMID: 20489169
24. Rudini N, Felici A, Giampietro C, Lampugnani M, Corada M, Swirsding K, et al. VE-cadherin is a critical endothelial regulator of TGF-beta signalling. EMBO J. 2008; 27(7): 993-1004. doi: 10.1038/emboj. 2008.46 PMID: 18337748
25. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, et al. A brain-specific microRNA regulates dendritic spine development. Nature 2006; 439(7074): 283-9 PMID: 16421561
26. UCSC Genome Bioinformatics Site. Available at https://genome.ucsc.edu/. Accessed 5 January 2016.
27. Jiang H, Wong WH. SeqMap: mapping massive amount of oligonucleotides to the genome. Bioinformatics 2008; 24(20): 2395-6 doi: 10.1093/bioinformatics/btn429 PMID: 18697769
28. The R Project for Statistical Computing. Available at http://www.r-project.org. Accessed 5 January 2016.
29. Govani FS, Giess A, Mollet IG, Begbie ME, Jones MD, Game L, et al. Directional next-generation RNA sequencing and examination of premature termination codon mutations in endoglin/hereditary haemorrhagic telangiectasia. Mol Syndromol. 2013; 4(4): 184-96 doi: 10.1159/000350208 PMID: 23801935
30. miRBase: the microRNA database. Available at http://www.mirbase.org. Accessed 5 January 2016.
31. Mollet IG, Ben-Dov C, Felício-Silva D, Grosso AR, Eleutério P, Alves R et al. Unconstrained mining of transcript data reveals increased alternative splicing complexity in the human transcriptome. Nucleic Acids Res. 2010; 38: 4740-54. doi: 10.1093/nar/gkq197 PMID: 20385588
32. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003; 4(5):P3. PMID: 12734009
33. Dolan M, Drabkin H, Hill DP, Li N, Sitnikov D, Bridges S, et al. Gene Ontology annotations and resources. Gene Ontology Consortium, Blake JA, Nucleic Acids Res. 2013; 41(Database issue):D530-5. doi: 10.1093/nar/gks1050 PMID: 23161678
34. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003 Nov; 13 (11):2498-504. PMID: 14597658
35. Pfaffl MW. A new mathematical model for relative quantification in real-time rt-PCR. Nuc Acid Res 2001; 29(9): e45
36. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3(7): RESEARCH0034
37. Kee Y, D'Andrea AD. Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest. 2012; 122(11): 3799-806 doi: 10.1172/JCI58321 PMID: 23114602
38. Chan KL, Hickson ID. New insights into the formation and resolution of ultra-fine anaphase bridges. Semin Cell Dev Biol. 2011; 22(8): 906-12. doi: 10.1016/j.semcdb.2011.07.001 PMID: 21782962
39. Croteau DL, Popuri V, Opresko PL, Bohr VA. Human RecQ Helicases in DNA Repair, Recombination, and Replication. Annu Rev Biochem. 2014; 83: 519-5 doi: 10.1146/annurev-biochem-060713-035428 PMID: 24606147
40. Chan KL, Palmai-Pallag T, Ying S, Hickson ID. Replication stress induces sister-chromatid bridging at fragile site loci in mitosis. Nat Cell Biol. 2009; 11(6): 753-60 doi: 10.1038/ncb1882 PMID: 19465922
41. Nikolova T, Dvorak M, Jung F, Adam I, Krämer E, Gerhold-Ay A, et al. The γH2AX Assay for Genotoxic and Non-Genotoxic Agents: Comparison of H2AX Phosphorylation With Cell Death Response. Toxicol Sci 2014; 140(1): 103-17 doi: 10.1093/toxsci/kfu066 PMID: 24743697
42. Roeckel N, Woerner SM, Kloor M, Yuan YP, Patsos G, Gromes R, et al. High frequency of LMAN1 abnormalities in colorectal tumors with microsatellite instability. Cancer Res. 2009; 69(1): 292-9 doi: 10.1158/0008-5472.CAN-08-3314 PMID: 19118014
43. Wen YY, Yang ZQ, Song M, Li BL, Zhu JJ, Wang EH. SIAH1 induced apoptosis by activation of the JNK pathway and inhibited invasion by inactivation of the ERK pathway in breast cancer cells. Cancer Sci. 2010; 101(1): 73-9 doi: 10.1111/j.1349-7006.2009.01339.x PMID: 19775288
44. Ahuja HS, Szanto A, Nagy L, Davies PJ. The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death. J Biol Regul Homeost Agents. 2003; 17(1): 29-45 PMID: 12757020
45. Collins AR. The Comet Assay for DNA Damage and Repair. Principles, Applications, and Limitations. Molecular Biotechnology. 2004 Humana Press Inc. ISBN 1073-6085/2004/26:3/249-261
46. de Feraudy S, Revet I, Bezrookove V, Feeney L, Cleaver JE. A minority of foci or pan-nuclear apoptotic staining of gammaH2AX in the S phase after UV damage contain DNA double-strand breaks. Proc Natl Acad Sci. 2010; 107: 6870-5 doi: 10.1073/pnas.1002175107 PMID: 20351298
47. Vaseva AV, Marchenk ND, Ji K, Tsirka SE, Holzmann S, Moll UM. P53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 2012; 149: 1536-48. doi: 10.1016/j.cell.2012.05.014 PMID: 22726440
48. Erster S, Mihara M, Kim RH, Petrenko O, Moll UM. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol. 2004 Aug; 24(15): 6728-41 PMID: 15254240
49. Zhang XP, Liu F, Wang W. Coordination between cell cycle progression and cell fate decision by the p53 and E2F1 pathways in response to DNA damage. J Biol Chem. 2010 Oct 8; 285(41): 31571-80. doi: 10.1074/jbc.M110.134650 PMID: 20685653
50. Lahav G, Rosenfeld N, Sigal A, Geva-Zatorsky N, Levine AJ, Elowitz MB, et al. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet. 2004; 36: 147-150. PMID: 14730303
51. Loewer A, Karanam K, Mock C, Lahav G. The p53 response in single cells is linearly correlated to the number of DNA breaks without a distinct threshold. BMC Biol. 2013; 11: 114 doi: 10.1186/1741-7007-11-114 PMID: 24252182
52. Finnamore H, Le Couteur J, Hickson M, Busbridge M, Whelan K, Shovlin CL. Hemorrhage-adjusted iron requirements, hematinics and hepcidin define hereditary hemorrhagic telangiectasia as a model of hemorrhagic iron deficiency. PLoS One 2013; 8(10): e76516 doi: 10.1371/journal.pone.0076516 PMID: 24146883
53. Alberts B, Johnson A, Lewis J, Morgan D, Raff M, Roberts K, et al. Molecular Biology of the Cell. Sixth edition. Garland Science. 2014. ISBN 9780815344322
54. Lindahl T. Instability and decay of the primary structure of DNA. Nature 1993; 362:709-715 PMID: 8469282
55. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ. 2006 Jun; 13 (6):941-50. PMID: 16601750
56. Zhang XP, Liu F, Wang W. Coordination between cell cycle progression and cell fate decision by the p53 and E2F1 pathways in response to DNA damage. J Biol Chem 2010 Oct 8; 285(41):31571-80. doi: 10.1074/jbc.M110.134650 PMID: 20685653
57. Tian X-P, Liu F, Zhang X-P, Li J, Wang W. A Two-Step Mechanism for Cell Fate Decision by Coordination of Nuclear and Mitochondrial p53 Activities. PLoS One. 2012; 7(6): e38164. doi: 10.1371/journal. pone.0038164 PMID: 22679490
58. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981; 1: 1293-4. PMID: 6112609
59. Muñoz-Bravo C, Gutiérrez-Bedmar M, Gómez-Aracena J, García-Rodríguez A, Navajas J F. Iron: protector or risk factor for cardiovascular disease? Still controversial. Nutrients 2013; 5: 2384-404 doi: 10.3390/nu5072384 PMID: 23857219
60. De Palma RG, Hayes VW, Chow BK, Shamayeva G, May PE, Zacharski LR. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: A substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial. J Vasc Surg. 2010; 51: 1498-1503. doi: 10.1016/j.jvs.2009.12.068 PMID: 20304584
61. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am. Heart J.2011; 162: 949-957. doi: 10.1016/j.ahj.2011.08.013 PMID: 22093213
62. Houschyar KS, Lüdtke R, Dobos GJ, Kalus U, Broecker-Preuss M, Rampp T, et al. Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: Results from a randomized clinical trial. BMC Med 2012; 10: 54. doi: 10.1186/1741-7015-10-54 PMID: 22647517
63. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, et al. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 2007; 297: 603-610 PMID: 17299195